List of Excipients in Branded Drug BICILLIN L-A

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	BICILLIN L-A	penicillin g benzathine	50090-1016	CARBOXYMETHYLCELLULOSE SODIUM
A-S Medication Solutions	BICILLIN L-A	penicillin g benzathine	50090-1016	LECITHIN, SOYBEAN
A-S Medication Solutions	BICILLIN L-A	penicillin g benzathine	50090-1016	METHYLPARABEN
A-S Medication Solutions	BICILLIN L-A	penicillin g benzathine	50090-1016	POVIDONE

Bicillin L-A Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 21, 2026

Bicillin L-A is a long-acting intramuscular suspension of benzathine penicillin G. Its commercial value is driven less by active-ingredient exclusivity than by sterile manufacturing, suspension performance, supply reliability, and clinical substitution barriers. The labeled excipient system includes sodium citrate, povidone, lecithin, and water for injection. These excipients are generally commoditized, but their combination, grade, processing sequence, particle-size control, and sterile fill-finish process create meaningful development and supply-chain opportunities.[1]

What is the formulation and excipient composition of Bicillin L-A?

Bicillin L-A contains penicillin G benzathine, a sparingly soluble penicillin salt designed to release penicillin G slowly after intramuscular administration. The product is supplied as a sterile injectable suspension rather than a solution.

Product attribute	Bicillin L-A profile
Active ingredient	Penicillin G benzathine
Route	Deep intramuscular injection
Dosages	600,000 units per 1 mL; 1.2 million units per 2 mL; 2.4 million units per 4 mL
Dosage form	Sterile injectable suspension
Primary clinical uses	Syphilis, streptococcal infections, rheumatic fever prophylaxis
Listed excipients	Sodium citrate, povidone, lecithin, water for injection
Preservative	No preservative is identified in the current U.S. labeling
U.S. regulatory status	FDA-approved prescription drug
Manufacturing challenge	Uniform resuspension, particle-size control, sterile processing, syringeability

The U.S. label identifies the excipients but does not disclose the complete quantitative formulation or manufacturing process. That distinction matters. A competitor can identify the broad excipient class while still facing substantial development work to reproduce sedimentation behavior, redispersibility, dose uniformity, injection force, and pharmacokinetics.[1]

What does each Bicillin L-A excipient do?

Sodium citrate functions primarily as a buffering and formulation-support agent. It can influence pH, ionic strength, suspension stability, and compatibility with penicillin G benzathine. Its concentration and order of addition may affect crystal growth and sedimentation.

Povidone acts as a polymeric stabilizer and wetting aid. Molecular weight, viscosity grade, peroxide level, and residual impurities can influence particle wetting, suspension viscosity, and long-term stability. Pharmaceutical-grade povidone is available from multiple suppliers, but equivalent compendial identity does not guarantee equivalent performance.

Lecithin supports wetting and dispersion of the hydrophobic or poorly water-soluble benzathine penicillin particles. Source, phospholipid composition, oxidation profile, and processing history may affect suspension quality.

Water for injection is the continuous phase and must meet compendial and sterile-manufacturing requirements. Water quality, endotoxin control, bulk holding time, and aseptic processing are central to the product’s quality system.

The formulation is therefore a simple excipient list with a technically sensitive manufacturing profile.

What excipient patents protect Bicillin L-A?

No current, commercially meaningful composition-of-matter exclusivity is expected to protect the basic Bicillin L-A excipient system. Penicillin G benzathine and the core formulation concept are several decades old, placing the original composition and formulation patents outside the ordinary U.S. patent term.

IP category	Bicillin L-A position	Commercial implication
Active-ingredient patent	Expired or historically obsolete	No meaningful composition barrier
Original formulation patent	Expected to be expired	Broad excipient combination is unlikely to block entry
Excipient composition patent	No publicly established blocking estate identified	Individual excipients are widely available
Manufacturing know-how	Potentially important and confidential	Process controls may be protected as trade secrets
Particle-size and suspension controls	Potentially patentable if novel	Narrow patents could cover process or performance parameters
Device or packaging patent	Possible for future presentations	Prefilled syringes and injection systems could create new rights
Method-of-use patent	Limited value for established indications	Clinical indications are old and heavily regulated
Trademark and trade dress	Commercially relevant	Brand recognition may support pricing and procurement preference

The practical IP barrier is more likely to be process know-how than a blocking patent. Relevant know-how may include milling or crystallization conditions, particle-size distribution, lecithin incorporation, mixing energy, deaeration, filling, container selection, and resuspension specifications.

When does Bicillin L-A lose exclusivity?

Bicillin L-A has no commercially important remaining new-drug patent exclusivity based on the age of benzathine penicillin G and its established formulation. The more relevant entry question is whether a competitor can obtain FDA approval for a sterile injectable suspension that is pharmaceutically and therapeutically equivalent.

The product’s competitive protection has historically come from:

• Limited manufacturing capacity for penicillin G benzathine.
• Difficult sterile suspension manufacturing.
• Specialized particle-size and physical-stability controls.
• Safety requirements for penicillin products.
• Procurement relationships with public-health agencies and hospitals.
• Clinical reluctance to substitute a long-established product in high-consequence infections.

A generic or alternative manufacturer does not need to overcome a modern composition patent to enter. It must demonstrate product quality, sterility, potency, stability, and bioequivalence under the applicable FDA pathway.

What is the FDA regulatory status and Orange Book position?

Bicillin L-A is an FDA-approved prescription product. The regulatory pathway for a competing product depends on the reference product designation, the applicable FDA product-specific guidance, and whether the proposed product qualifies as an ANDA-based generic or requires a 505(b)(2) application.

For an injectable suspension, the key regulatory issues are likely to include:

1. Active ingredient sameness. The product must contain penicillin G benzathine in the relevant strength.
2. Dosage-form equivalence. The suspension must match the reference product’s route and dosage form.
3. Inactive ingredient justification. Excipients must be appropriate for intramuscular use and supported by safety and quality data.
4. Comparative characterization. Particle size, morphology, crystal form, viscosity, pH, density, redispersibility, and syringeability may be important.
5. Sterility and endotoxin controls. The product requires validated aseptic or terminal-sterilization controls compatible with the formulation.
6. Bioequivalence. The sponsor must address the prolonged-release profile created by the benzathine salt and suspension.
7. Container closure. Vial, stopper, syringe, and needle compatibility can influence extractables, adsorption, dose delivery, and stability.

The FDA Orange Book should be reviewed for the current reference listing, patents, and exclusivity codes before a filing or freedom-to-operate opinion. Older injectable products may have a sparse or outdated patent listing profile, and the commercial barrier may be regulatory execution rather than Orange Book litigation.[2]

Can excipients trigger a Paragraph IV challenge?

A Paragraph IV certification is relevant only when an ANDA applicant seeks to market a product covered by a listed patent. For Bicillin L-A, the aged active ingredient and formulation make a significant modern Paragraph IV barrier less likely than for newer small-molecule products.

Potential patent disputes could still arise from:

• A later-listed formulation patent.
• A prefilled syringe or injection-device patent.
• A novel particle-size specification.
• A manufacturing process patent.
• A narrow stability or suspension patent.
• A method-of-use patent tied to a newly approved indication.

A competitor should separate freedom to operate around the active ingredient from freedom to operate around manufacturing and delivery systems. The first is likely low risk; the second requires current patent searching in the United States and other target markets.

How strong is the Bicillin L-A patent estate?

The patent estate is likely weak as a blocking asset but potentially meaningful as a process and know-how asset.

Patent-strength factor	Assessment
Active ingredient	Weak; legacy compound
Core excipients	Weak; established pharmaceutical materials
Broad formulation	Weak unless supported by an unusually narrow surviving claim
Manufacturing process	Moderate potential for confidential know-how
Sterile suspension process	Moderate technical barrier
Delivery device	Moderate to strong if a new proprietary presentation is developed
New indications	Limited historical protection; possible future opportunity
Trade secrets	Commercially important
Regulatory exclusivity	Dependent on any future supplemental approvals

The absence of a strong composition patent does not mean the product is easy to replicate. Suspension injectables can be difficult to match without access to manufacturing history and analytical methods.

What formulation patents could create new commercial protection?

A new Bicillin L-A-type product could seek patent protection around a differentiated presentation rather than the old excipient combination.

Improved suspension stability

A patent could target a defined particle-size distribution, sedimentation rate, redispersibility threshold, or viscosity range. Claims would need to distinguish the product from historical benzathine penicillin suspensions and show a measurable technical benefit.

Prefilled syringes

A prefilled syringe could reduce preparation time and dosing errors. Patentable features may include:

• Syringe geometry optimized for viscous suspensions.
• Needle gauge and injection-force control.
• Low-dead-space delivery.
• Agitation or resuspension mechanisms.
• Container-closure compatibility.
• Dose-specific presentations.

The commercial benefit is clearest in public-health programs, emergency departments, pediatric settings, and high-volume clinics.

Reduced injection burden

Bicillin L-A is already long acting, but a formulation that improves injection volume, resuspension, or administration time could have commercial value. Any change that alters release kinetics would require strong pharmacokinetic and clinical support.

Temperature-stable presentations

A formulation or package that improves stability during transport and storage could address supply-chain constraints. Claims could focus on stability under defined temperature excursions, low-temperature exposure, or prolonged storage.

Combination presentations

A combination of benzathine penicillin G with another active ingredient would be a new drug product rather than a routine generic substitution. This strategy would carry substantially higher clinical, regulatory, and IP risk.

What excipient supply opportunities exist for Bicillin L-A?

The most immediate opportunities are in qualified raw-material supply and contract development rather than exclusive ownership of the excipient formula.

Pharmaceutical-grade sodium citrate

Suppliers can compete on low elemental impurities, consistent particle size, validated microbial control, and reliable global supply. The product’s sensitivity to pH and ionic strength makes lot-to-lot consistency relevant even though sodium citrate is a commodity excipient.

High-purity povidone

A supplier can differentiate through:

• Controlled molecular-weight distribution.
• Low peroxide content.
• Low bioburden.
• Sterile or low-endotoxin processing.
• Documentation for injectable use.
• Dual manufacturing sites.

High-purity povidone may be especially relevant if oxidation or viscosity drift affects suspension stability.

Injectable-grade lecithin

Lecithin has greater variability than sodium citrate. Supplier opportunities include defined phospholipid composition, controlled oxidation, animal-origin documentation, allergen controls, and injectable-grade quality systems. Plant-derived and synthetic phospholipid alternatives could support a differentiated development program, but they would require compatibility and regulatory evaluation.

Custom excipient systems

A supplier could offer a prequalified suspension platform containing citrate buffer, polymeric wetting aid, and phospholipid dispersant. The value would come from formulation support, analytical methods, regulatory documentation, and supply continuity rather than from the individual excipients.

Contract manufacturing and fill-finish

The strongest commercial opportunity may be a specialist sterile manufacturer capable of:

• Handling penicillin-class beta-lactam segregation requirements.
• Producing uniform sterile suspensions.
• Filling 1 mL, 2 mL, and 4 mL dose volumes.
• Validating resuspension and dose withdrawal.
• Supporting vial and prefilled-syringe formats.
• Maintaining dedicated containment and cleaning validation.

Penicillin manufacturing requires careful facility design because beta-lactam cross-contamination can create serious patient-safety and regulatory risks.

Which companies are positioned to challenge or supply Bicillin L-A?

The competitive field includes the originator or marketed-product holder, generic injectable manufacturers, sterile contract development organizations, excipient suppliers, and public-health procurement partners.

The most credible challengers would need experience in:

• Sterile injectable suspensions.
• Long-acting intramuscular products.
• Penicillin or other beta-lactam manufacturing.
• Complex generic development.
• Government and institutional procurement.
• Global regulatory filings.

Ordinary oral-generic manufacturers are less well positioned because the critical capabilities are sterile suspension development and dedicated beta-lactam production.

The market also includes suppliers of sodium citrate, povidone, lecithin, sterile containers, elastomeric closures, and injection devices. A supplier that secures a qualified second source may obtain more durable commercial value than one that sells an interchangeable commodity excipient.

What generic entry risks exist for Bicillin L-A?

The main generic-entry risks are technical and operational.

Risk	Likely impact
Particle-size mismatch	Altered release, sedimentation, or dose uniformity
Poor redispersibility	Incomplete dose delivery
High injection force	Administration failure or needlestick risk
Crystal-form variation	Stability and pharmacokinetic differences
Lecithin oxidation	Physical instability or impurity formation
Povidone variability	Viscosity and suspension-performance changes
Sterile manufacturing failure	Batch rejection or regulatory action
Beta-lactam cross-contamination	Facility shutdown and liability exposure
Limited API supply	Delayed launch and high inventory requirements
Public-health procurement concentration	Price pressure and volume volatility

A successful entrant would likely need a differentiated quality package, dependable API access, and a manufacturing network capable of maintaining supply during demand spikes.

How does Bicillin L-A compare with alternative long-acting anti-infective opportunities?

Bicillin L-A has a distinct commercial profile because its clinical role is tied to established treatment guidelines and public-health programs.

Opportunity	Excipient complexity	Patent opportunity	Regulatory burden	Commercial angle
Bicillin L-A generic	High	Low to moderate	High	Supply reliability and price
Improved benzathine suspension	High	Moderate	High	Better administration and stability
Prefilled Bicillin-type syringe	Moderate to high	Moderate	Moderate to high	Workflow and dosing efficiency
New long-acting antibiotic	High	High	Very high	New clinical value
Oral penicillin alternative	Low	Low	Moderate	Convenience, but weaker substitution
Long-acting biologic anti-infective	Very high	High	Very high	Premium specialty market

Bicillin L-A remains attractive for a focused sterile-injectable strategy, but its economics are more likely to depend on volume, procurement contracts, and reliable supply than on premium patent pricing.

What licensing deals and partnerships are commercially relevant?

Potential transactions fall into four categories:

1. Product rights licensing. A regional manufacturer licenses marketing rights for an approved or near-approved benzathine penicillin product.
2. Manufacturing partnerships. An originator or generic sponsor contracts sterile suspension production to a qualified facility.
3. Excipient qualification agreements. An excipient supplier becomes a validated primary or secondary source.
4. Device and packaging collaborations. A pharmaceutical company partners with a syringe or injection-device manufacturer.

The most valuable deal terms would likely address minimum purchase volumes, dual sourcing, technology transfer, change-control obligations, regulatory ownership, and supply interruption remedies. A formulation license without manufacturing transfer may have limited value because the key barrier is reproducible process execution.

What revenue exposure and commercial opportunities exist?

Revenue exposure is concentrated in products used for syphilis treatment, congenital syphilis prevention, rheumatic fever prophylaxis, and institutional infectious-disease programs. Demand can increase abruptly when public-health authorities identify shortages or disease outbreaks.

Commercial opportunities include:

• A second-source U.S. supplier.
• Dose-specific prefilled syringes.
• Improved packaging for cold-chain or temperature excursions.
• Contract sterile manufacturing.
• Qualified excipient dual sourcing.
• Regional supply agreements.
• Government stockpiling.
• Injectable-grade lecithin and povidone supply.
• Analytical testing packages for suspension equivalence.
• Global-market versions for countries dependent on imported benzathine penicillin.

Revenue forecasts should account for tender pricing, government purchasing, wholesaler concentration, API availability, and the possibility that a shortage-driven market normalizes after additional capacity enters.

What geographic coverage matters for Bicillin L-A?

The United States is commercially important because of FDA approval, public-health demand, and the Orange Book framework. Europe, Latin America, and selected Asian markets may present opportunities where benzathine penicillin remains central to syphilis and rheumatic fever programs.

A global strategy must address:

• Country-specific product registrations.
• Different pharmacopeial requirements.
• Local pharmacovigilance obligations.
• Import and cold-chain controls.
• Government tender rules.
• Local manufacturing incentives.
• Penicillin facility segregation.
• Regional API and excipient sourcing.

The strongest geographic strategy is usually a combination of U.S. approval, selected high-volume public-health markets, and regional supply partnerships.

Key Takeaways

• Bicillin L-A is a sterile intramuscular suspension of benzathine penicillin G.
• Its labeled excipients are sodium citrate, povidone, lecithin, and water for injection.
• The broad excipient combination is unlikely to provide meaningful current composition-patent protection.
• Manufacturing know-how, particle-size control, sterile processing, and beta-lactam containment are the main barriers.
• A generic entrant would face substantial formulation, bioequivalence, sterility, and supply-chain requirements.
• The best excipient opportunities are high-purity injectable-grade materials, qualified second sources, and custom suspension systems.
• Prefilled syringes and improved stability could support new formulation or device patents.
• Commercial returns are likely to depend on reliable supply, government procurement, and manufacturing scale rather than premium exclusivity.
• Current FDA Orange Book and patent records should control any filing, licensing, or litigation decision.[2]

FAQs About Bicillin L-A Excipients and Commercial Strategy

Is lecithin in Bicillin L-A a patentable competitive advantage?

Lecithin itself is not a meaningful proprietary barrier. A defined phospholipid composition, oxidation specification, or processing method could support narrower patent claims if it produces a demonstrated stability or delivery benefit.

Can a generic company replace povidone in Bicillin L-A?

A replacement may be possible, but the sponsor would need to establish that the alternative excipient does not adversely affect suspension performance, stability, sterility, injection characteristics, or bioequivalence.

Is Bicillin L-A a biologic with biosimilar risk?

No. Bicillin L-A is a chemically defined small-molecule drug product. Competitors would generally be evaluated through generic or 505(b)(2)-type pathways, not the biosimilar pathway used for biological products.

Could a prefilled syringe extend Bicillin L-A exclusivity?

A prefilled syringe could create device or formulation IP and may receive regulatory protection tied to a new presentation. It would not automatically restore exclusivity for the underlying benzathine penicillin G product.

What is the most defensible commercial position in the Bicillin L-A value chain?

A qualified sterile manufacturer or excipient supplier with validated injectable-grade materials, dual-source capability, and regulatory documentation is likely to have a stronger defensible position than a supplier relying only on commodity excipient production.

References

1. Pfizer Inc. (2024). Bicillin L-A (penicillin G benzathine) injectable suspension: U.S. prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention.

5. Centers for Disease Control and Prevention. (2024). Sexually transmitted infections treatment guidelines: Syphilis. U.S. Department of Health and Human Services.